Vascular Inflammation and the Renin-Angiotensin System
Top Cited Papers
- 1 August 2002
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (8), 1257-1266
- https://doi.org/10.1161/01.atv.0000021412.56621.a2
Abstract
It is now well established that vascular inflammation is an independent risk factor for the development of atherosclerosis. In otherwise healthy patients, chronic elevations of circulating interleukin-6 or its biomarkers are predictors for increased risk in the development and progression of ischemic heart disease. Although multifactorial in etiology, vascular inflammation produces atherosclerosis by the continuous recruitment of circulating monocytes into the vessel wall and by contributing to an oxidant-rich inflammatory milieu that induces phenotypic changes in resident (noninflammatory) cells. In addition, the renin-angiotensin system (RAS) has important modulatory activities in the atherogenic process. Recent work has shown that angiotensin II (Ang II) has significant proinflammatory actions in the vascular wall, inducing the production of reactive oxygen species, inflammatory cytokines, and adhesion molecules. These latter effects on gene expression are mediated, at least in part, through the cytoplasmic nuclear factor-κB transcription factor. Through these actions, Ang II augments vascular inflammation, induces endothelial dysfunction, and, in so doing, enhances the atherogenic process. Our recent studies have defined a molecular mechanism for a biological positive-feedback loop that explains how vascular inflammation can be self-sustaining through upregulation of the vessel wall Ang II tone. Ang II produced locally by the inflamed vessel induces the synthesis and secretion of interleukin-6, a cytokine that induces synthesis of angiotensinogen in the liver through a janus kinase (JAK)/signal transducer and activator of transcription (STAT)-3 pathway. Enhanced angiotensinogen production, in turn, supplies more substrate to the activated vascular RAS, where locally produced Ang II synergizes with oxidized lipid to perpetuate atherosclerotic vascular inflammation. These observations suggest that one mechanism by which RAS antagonists prevent atherosclerosis is by reducing vascular inflammation. Moreover, antagonizing the vascular nuclear factor-κB and/or hepatic JAK/STAT pathways may modulate the atherosclerotic process.Keywords
This publication has 65 references indexed in Scilit:
- Identification of NF-κB-Dependent Gene Networks in Respiratory Syncytial Virus-Infected CellsJournal of Virology, 2002
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- Mechanisms for Inducible Control of Angiotensinogen Gene TranscriptionHypertension, 1996
- Elevated plasma interleukin-6 levels in patients with acute myocardial infarctionAmerican Heart Journal, 1993
- Molecular basis of human hypertension: Role of angiotensinogenCell, 1992
- Association of the Renin-Sodium Profile with the Risk of Myocardial Infarction in Patients with HypertensionNew England Journal of Medicine, 1991
- Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.Hypertension, 1990
- Circulating and tissue angiotensin systems.JCI Insight, 1987
- Proteolytic degradation of low density lipoproteins by arterial smooth muscle cells: The role of individual cathepsinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981
- Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects.Hypertension, 1979